

LFIR # 1668

1. Project Title Jordan Avi Ogman Foundation to Cure Pediatric Brain Disease

2. Senate Sponsor Tina Polsky

3. Date of Request 02/20/2023

4. Project/Program Description

The Jordan Avi Ogman Foundation is researching and developing cures for TECPR2, a rare, fatal, and progressive, neurodegenerative disease that affects children. The gene therapy cure being developed will save the lives of children battling pediatric brain disease. The research is enabling the advancement of translational understanding to cure related lysosomal storage disease affecting Florida's elderly population affected by Parkinson's, Alzheimer's, ALS, and similar neurodegenerative disease.

5. State Agency to receive requested funds

Department of Health

State Agency contacted? No

6. Amount of the Nonrecurring Request for Fiscal Year 2023-2024

Type of Funding	Amount
Operations	50,000
Fixed Capital Outlay	0
Total State Funds Requested	50,000

7. Total Project Cost for Fiscal Year 2023-2024 (including matching funds available for this project)

Type of Funding	Amount	Percentage
Total State Funds Requested (from question #6)	50,000	100%
Matching Funds		
Federal	0	0%
State (excluding the amount of this request)	0	0%
Local	0	0%
Other	0	0%
Total Project Costs for Fiscal Year 2023-2024	50,000	100%

8. Has this project previously received state funding? No

Fiscal Year	Amount		Specific	Vetoed
(уууу-уу)	Recurring	Nonrecurring	Appropriation #	

9. Is future funding likely to be requested?

No	

a. If yes, indicate nonrecurring amount per year.

b. Describe the source of funding that can be used in lieu of state funding.

Outside of state funding, the research and development of TECPR2 neurodegenerative disease is a grassroots effort by families affected by genetic brain disease. The pace of which donations are raised are preventing the scientists from receiving the necessary funding to develop the cure.

10. Has the entity requesting this project received any federal assistance related to the COVID-19 pandemic?



No

If yes, indicate the amount of funds received and what the funds were used for.

Complete questions 11 and 12 for Fixed Capital Outlay Projects

11. Status of Construction

a. What is the current phase of the project?

OPlanning ODesign OConstruction

- b. Is the project "shovel ready" (i.e permitted)?
- c. What is the estimated start date of construction?
- d. What is the estimated completion date of construction?
- 12. List the owners of the facility to receive, directly or indirectly, any fixed capital outlay funding. Include the relationship between the owners of the facility and the entity.

13. Details on how the requested state funds will be expended

Spending Category	Description	Amount
Administrative Costs:		
Executive Director/Project Head Salary and Benefits		0
Other Salary and Benefits		0
Expense/Equipment/Travel/Supplies/ Other		0
Consultants/Contracted Services/Study		0
Operational Costs: Other		
Salary and Benefits		0
Expense/Equipment/Travel/Supplies/ Other		0
Consultants/Contracted Services/Study	Our team of Scientists have been conducing research to develop the life-saving gene therapy cure for TECPR2, a rare, fatal, and progressive, neurodegenerative, genetic disease in Kids. Now that the research is complete, and as we further develop the gene therapy constructs to examine efficacy and safety, we are progressing towards the manufacturing, production, and associated costs of developing the vector to be perfected so that i provides the desired outcome.	50,000
Fixed Capital Construction/Majo	r Renovation:	
Construction/Renovation/Land/ Planning Engineering		0
Total State Funds Requested (m	ust equal total from question #6)	50,000

14. Program Performance

a. What specific purpose or goal will be achieved by the funds requested?



The purpose and/or goal is research and development of the life-saving gene therapy cure for TECPR2, a rare, fatal, and progressive, neurodegenerative, Pediatric genetic disease. The gene therapy cure for TECPR2 being developed to save the lives of the children battling this debilitating disease will enable the research to advance as its translational to understanding how to further develop gene therapy for similar devastating neurodegenerative disease for children throughout our state of Florida.

b. What activities and services will be provided to meet the intended purpose of these funds?

Research and development of the life-saving gene therapy cure for TECPR2, a rare, fatal, and progressive, neurodegenerative, Pediatric genetic disease. The gene therapy cure for TECPR2 being developed to save the lives of the children battling this debilitating disease will enable the research to advance as its translational to understanding how to further develop gene therapy for similar devastating neurodegenerative disease for children throughout our state of Florida.

c. What direct services will be provided to citizens by the appropriation project?

Direct services provided to citizens will be the life-saving gene therapy cure.

d. Who is the target population served by this project? How many individuals are expected to be served?

Pediatric population of children battling rare, fatal, and progressive, neurodegenerative, genetic disease.

e. What is the expected benefit or outcome of this project? What is the methodology by which this outcome will be measured?

Benefit is life-saving gene therapy cure to cure TECPR2 neurodegenerative disease in children.

f. What are the suggested penalties that the contracting agency may consider in addition to its standard penalties for failing to meet deliverables or performance measures provided for the contract?

Failure to meet performance is unacceptable, as our kids require this life-saving gene therapy cure, so we will continue to research and develop the cure until it is perfected for our children in the State of Florida.

15. Requester Contact Information

a. First Name	David	Last Name	Ogman
b. Organization	Jordan Avi Ogman Found	ation	
c. E-mail Address	David.M.Ogman@gmail.c	om	
d. Phone Number	(561)945-5040	Ext.	

16. Recipient Contact Information

a. Organization Jordan Avi Ogman Foundation

b. Municipality and County Palm Beach

c. Organization Type

□For Profit Entity

☑Non Profit 501(c)(3)

□Non Profit 501(c)(4)

□Local Entity

□University or College



LFIR # 1668

□Other	(please	specify)
--------	---------	----------

d. First Name	David	Last Name Ogman	
e. E-mail Address	David.M.Ogman@gmail.c	com	
f. Phone Number	(561)945-5040		
17. Lobbyist Contact I	nformation		
a. Name	None		

a. Name	None
b. Firm Name	None
c. E-mail Address	
d. Phone Number	